A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Miricorilant Tablet Formulations Following Single and Multiple Oral Doses in Healthy Participants
Latest Information Update: 19 Dec 2020
At a glance
- Drugs Miricorilant (Primary)
- Indications Non-alcoholic steatohepatitis; Weight gain
- Focus Adverse reactions
- Sponsors Corcept Therapeutics
- 19 Dec 2020 New trial record